Skip to main content
Fig. 2 | Renal Replacement Therapy

Fig. 2

From: Virological response to daclatasvir and asunaprevir combination therapy for chronic hepatitis C virus genotype 1b infection in dialysis patients: a prospective, multicenter study

Fig. 2

Change in HCV-RNA levels during treatment with daclatasvir and asunaprevir in complete, relapse, and breakthrough patients. HCV-RNA levels at baseline, at weeks 0, 2, 4, 8, 12, 16, 20, and 24, and posttreatment at weeks 4, 8, 12, and 24. LLQ lower limit of quantification (IU/mL). Complete indicates patients with a mean sustained virological response at 24 weeks after the treatment ended

Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us